BI 685509 is an NO-independent sGC activator that reduces portal pressure, fibrosis and extrahepatic complications of portal hypertension in preclinical models of cirrhosis (data on file) and is currently being investigated in patients with portal hypertension to reduce portal pressure and to slow cirrhosis progression. Here, SGCB is linked to liver disorder.